Literature DB >> 20175460

Evaluation of the interplay effect when using RapidArc to treat targets moving in the craniocaudal or right-left direction.

Laurence Court1, Matthew Wagar, Ross Berbeco, Adam Reisner, Brian Winey, Debbie Schofield, Dan Ionascu, Aaron M Allen, Richard Popple, Tania Lingos.   

Abstract

PURPOSE: We have investigated the dosimetric errors caused by the interplay between the motions of the LINAC and the tumor during the delivery of a volume modulated arc therapy treatment. This includes the development of an IMRT QA technique, applied here to evaluate RapidArc plans of varying complexity.
METHODS: An IMRT QA technique was developed, which involves taking a movie of the delivered dose (0.2 s frames) using a 2D ion chamber array. Each frame of the movie is then moved according to a respiratory trace and the cumulative dose calculated. The advantage of this approach is that the impact of turning the beam on at different points in the respiratory trace, and of different types of motion, can be evaluated using data from a single irradiation. We evaluated this technique by comparing with the results when we actually moved the phantom during irradiation. RapidArc plans were created to treat a 62 cc spherical tumor in a lung phantom (16 plans) and a 454 cc irregular tumor in an actual patient (five plans). The complexity of each field was controlled by adjusting the MU (312-966 MU). Each plan was delivered to a phantom, and a movie of the delivered dose taken using a 2D ion chamber array. Patient motion was modeled by shifting each dose frame according to a respiratory trace, starting the motion at different phases. The expected dose distribution was calculated by blurring the static dose distribution with the target motion. The dose error due to the interplay effect was then calculated by comparing the delivered dose with the expected dose distribution. Peak-to-peak motion of 0.5, 1.0, and 2.0 cm in the craniocaudal and right-left directions, with target periods of 3 and 5 s, were evaluated for each plan (252 different target motion/plan combinations).
RESULTS: The daily dose error due to the interplay effect was less than 10% for 98.4% of all pixels in the target for all plans investigated. The percentage of pixels for which the daily dose error could be larger than 5% increased with increasing plan complexity (field MU), but was less than 15% for all plans if the motion was 1 cm or less. For 2 cm motion, the dose error could be larger than 5% for 40% of pixels, but was less than 5% for more than 80% of pixels for MU < 550, and was less than 10% for 99% of all pixels. The interplay effect was smaller for 3 s periods than for 5 s periods.
CONCLUSIONS: The interplay between the motions of the LINAC and the target can result in an error in the delivered dose. This effect increases with plan complexity, and with target magnitude and period. It may average out after many fractions.

Entities:  

Mesh:

Year:  2010        PMID: 20175460     DOI: 10.1118/1.3263614

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  20 in total

1.  The dosimetric impact of inversely optimized arc radiotherapy plan modulation for real-time dynamic MLC tracking delivery.

Authors:  Marianne Falk; Tobias Larsson; Paul Keall; Byung Chul Cho; Marianne Aznar; Stine Korreman; Per Poulsen; Per Munck Af Rosenschold
Journal:  Med Phys       Date:  2012-03       Impact factor: 4.071

2.  RapidArc vs intensity-modulated radiation therapy for hepatocellular carcinoma: a comparative planning study.

Authors:  J M Park; K Kim; E K Chie; C H Choi; S J Ye; S W Ha
Journal:  Br J Radiol       Date:  2012-07       Impact factor: 3.039

3.  Interplay effect modeling in stereotactic body radiotherapy treatment of liver cancer using volumetric modulated arc therapy.

Authors:  Deepak Thaper; Arun S Oinam; Rose Kamal; Gaganpreet Singh; Bhumika Handa; Vivek Kumar; Hanuman P Yadav
Journal:  Phys Eng Sci Med       Date:  2021-02-04

4.  Safety and benefit of using a virtual bolus during treatment planning for breast cancer treated with arc therapy.

Authors:  Marguerite Tyran; Agnes Tallet; Michel Resbeut; Marjorie Ferre; Veronique Favrel; Pierre Fau; Laurence Moureau-Zabotto; Julien Darreon; Laurence Gonzague; Ahcene Benkemouche; Leonel Varela-Cagetti; Naji Salem; Bertrand Farnault; Marie-Aimee Acquaviva; Hugues Mailleux
Journal:  J Appl Clin Med Phys       Date:  2018-06-30       Impact factor: 2.102

5.  Target tracking using DMLC for volumetric modulated arc therapy: a simulation study.

Authors:  Baozhou Sun; Dharanipathy Rangaraj; Lech Papiez; Swetha Oddiraju; Deshan Yang; H Harold Li
Journal:  Med Phys       Date:  2010-12       Impact factor: 4.071

6.  Multiple anatomy optimization of accumulated dose.

Authors:  W Tyler Watkins; Joseph A Moore; James Gordon; Geoffrey D Hugo; Jeffrey V Siebers
Journal:  Med Phys       Date:  2014-11       Impact factor: 4.071

7.  Under-reported dosimetry errors due to interplay effects during VMAT dose delivery in extreme hypofractionated stereotactic radiotherapy.

Authors:  Tobias Gauer; Thilo Sothmann; Oliver Blanck; Cordula Petersen; René Werner
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

8.  Off-target-isocentric approach in non-coplanar Volumetric Modulated Arc Therapy (VMAT) planning for lung SBRT treatments.

Authors:  Sangroh Kim; Tzu-Chi Tseng
Journal:  J Radiosurg SBRT       Date:  2015

9.  Effects on the photon beam from an electromagnetic array used for patient localization and tumor tracking.

Authors:  Wei Zou; Ricardo Betancourt; Lingshu Yin; James Metz; Stephen Avery; Alireza Kassaee
Journal:  J Appl Clin Med Phys       Date:  2013-05-06       Impact factor: 2.102

10.  Stereotactic Body radiation therapy for liver tumors with or without rotational intensity modulated radiation therapy.

Authors:  Elodie Nouhaud; Gilles Créhange; Adèle Cueff; Magali Quivrin; Magali Rouffiac-Thouant; Laurent Mineur; Robin Garcia; Jérôme Chamois; Philippe Maingon
Journal:  BMC Res Notes       Date:  2013-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.